Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3 versus 6 months of adjuvant modified FOLFOX6 in stage III colon cancer
2009-010384-16Phase 3Active
- Sponsor
- GERCOR
- Start
- Mar 2009
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fluorouracil, folinic acid and oxaliplatin in colon cancer (2 arms), sponsored by GERCOR. Primary endpoint: Disease-free survival. Started Mar 2009; status: active.
02
Drugs
fluorouracilfolinic acidoxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2009-010384-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-010384-16.